These factors are represented by SRY-Box Transcription Factor 2 (Sox2) and octamer-binding transcription factor 4 (Oct4) whose activation promotes the suppression of both innate and adaptive immune responses maintaining glioma cell stemness and tumor-propagating potential (38). This evidence concerns the gene SOX2 and central nervous system cancer.